The objective Psoriasis Area Severity Index: A randomised controlled pilot study comparing the effectiveness of cyclosporine and methotrexate using an objective PASI (oPASI)

Abstract

A randomised controlled pilot study was performed to compare the clinical effectiveness of cyclosporine and methotrexate, using a new objective severity assessment method, which we then compared with the Psoriasis Area Severity Index (PASI) for usefulness and reliability.

Psoriatic patients with psoriatic lesions over 5% of body surface area were enrolled and underwent 16 weeks of treatment with either cyclosporine or methotrexate. In the cyclosporine group, the initial dose was 150 mg/day for females and 200 mg/day for males.

This article is protected by copyright. All rights reserved.

http://ift.tt/2k1JjDW